QCG
KROS icon

Quadrant Capital Group’s Keros Therapeutics KROS Stock Holding History

Quadrant Capital Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-251
Closed -$5.11K – 2767
2025
Q4 		$5.11K Hold
251
– – ﹤0.01% 2371
2025
Q3 		$3.97K Buy
+251
New +$3.71K ﹤0.01% 2362
2023
Q3 		– Sell
-6
Closed -$242 – 2735
2023
Q2 		$242 Buy
+6
New +$263 ﹤0.01% 2643

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Quadrant Capital Group's KROS Position: Q1 2026 in Review

Quadrant Capital Group sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 251 shares — an estimated $5.11K sold.

Quadrant Capital Group first reported a position in KROS in Q2 2023 and held it in 3 quarters. The position peaked at $5.11K in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Quadrant Capital Group reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 251 Keros Therapeutics shares in Q1 2026, an estimated $5.11K.
  • Quadrant Capital Group first reported a position in Keros Therapeutics in Q2 2023 and held it in 3 quarters.
  • Quadrant Capital Group's Keros Therapeutics position peaked at $5.11K in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.